Printer Friendly

U.S. DRUG TESTING RECEIVES FDA MARKETING APPROVAL

 RANCHO CUCAMONGA, Calif., May 4 /PRNewswire/ -- Gary S. Wolff, chief financial officer, announced today that U.S. Drug Testing Inc. (USDT), a wholly owned subsidiary of U.S. Alcohol Testing of America Inc. (USAT) (AMEX: AAA), has received notice from the Food and Drug Administration (FDA) that its 510(k) application, submitted on Feb. 22, 1993, has been determined to be substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments.
 The application submitted is for the assay which detects cocaine and its metabolite, benzoylegonine utilizing the Flow Immunosensor technology.
 The notification from the FDA permits the company to begin marketing the device subject to the general control provisions of the Medical Device Amendments Act including requirements for registration, listing of the device, good manufacturing practice and labeling. The company, however, does not intend to begin marketing the technology until it has proven equivalency of additional assays being developed, including those for marijuana, amphetamines, PCP and opiates, which include heroin and morphine. Submissions to the FDA of these assays are expected over the next several months.
 The FDA notification of marketing approval came just 62 days after the application was submitted, far ahead of the average clearance time. According to the Jan. 8, 1993, edition of Devices and Diagnostics Letter, "The average 510(k) clearance time rose from 102 to 126 days in fiscal 1992 and has risen to over 130 days since then and is expected to continue lengthening."
 The Flow Immunosensor Technology provides a more sensitive method for testing for drugs of abuse while significantly decreasing the assay time and cost. This technology, developed by scientists at the Naval Research Laboratory, was licensed to the company in January 1992 from the U.S. government through the Technology Transfer Act. A subsequent one-year Cooperative Research and Development Agreement was signed in April 1992.
 U.S. Alcohol Testing of America Inc. manufactures evidential and screening equipment for alcohol breath testing analysis used by law enforcement agencies and industry.
 -0- 5/4/93
 /CONTACT: Gary S. Wolff, CFO of U.S. Alcohol Testing of America, 909-466-8378/
 (AAA)


CO: U.S. Alcohol Testing of America Inc.; U.S. Drug Testing Inc. ST: California IN: HEA SU:

JL-LS -- LA013 -- 4148 05/04/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 4, 1993
Words:384
Previous Article:MARINE HARVEST INTERNATIONAL, INC. REPORTS SUBSTANTIAL INCREASE IN SECOND QUARTER RESULTS
Next Article:ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 FIRST QUARTER RESULTS
Topics:


Related Articles
EPITOPE RECEIVES ADDITIONAL APPROVAL FOR EXPORT OF ORAL SPECIMEN COLLECTION DEVICE
DISEASE DETECTION INTERNATIONAL FILES 'IND' APPLICATION WITH FDA SEEKING APPROVAL TO BEGIN FORMAL CLINICAL STUDIES FOR SEVEN-MINUTE AIDS TEST
BIOPOOL RECEIVES FDA APPROVAL TO MARKET MINUTEX(TM) D-DIMER AND SPECTROLYSE PL/PAI TEST KITS
U.S. ALCOHOL TESTING SUBMITS NEW 510(k) APPLICATION TO FDA
U.S. DRUG TESTING INC. RECEIVES FDA MARKETING APPROVAL ON FLOW IMMUNOASSAY SYSTEM, MODEL 9000
COMPANY SUBMITS 510(k) APPLICATION TO FDA FOR PHENCYCLIDINE ASSAY
BIOPOOL RECEIVES APPROVAL TO MARKET CALIBRATOR FOR USE WITH U.S. DRUG TESTING INC. SYSTEM
GENSIA SUBMITS NDA AMENDMENT FOR GenESA(R) SYSTEM IN U.S.
BIOPOOL INTERNATIONAL RECEIVES FDA APPROVAL TO MARKET TWO NEW CHEMISTRY REAGENT SYSTEMS
CHEMTRAK GAINS RETURN OF MARKETING RIGHTS FOR HOME CHOLESTEROL TEST

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters